Key points from article :
Denali Therapeutics, a company developing treatments for neurodegenerative diseases, raised $500 million from investors.
The funding will support ongoing research and development of new drugs.
Focuses on treatments for genetically linked neurodegenerative diseases, designing drugs that cross the blood-brain barrier for better brain delivery, and identification of biomarkers.
Targets areas like degenogenes (genes associated with neurodegeneration) and lysosomal function in brain cells.
It also explores opportunities in glial biology (correcting dysfunction in cells) and cellular homeostasis.
New funding will advance their blood-brain barrier-crossing Transport Vehicle technology technology for drug delivery.
This investment highlights the potential of Denali's technology for treating brain diseases.
